204 related articles for article (PubMed ID: 32972640)
1. Pharmacologic Glycemic Management of Type 2 Diabetes in Adults: 2020 Update.
; Lipscombe L; Butalia S; Dasgupta K; Eurich DT; MacCallum L; Shah BR; Simpson S; Senior PA
Can J Diabetes; 2020 Oct; 44(7):575-591. PubMed ID: 32972640
[No Abstract] [Full Text] [Related]
2. Pharmacologic Glycemic Management of Type 2 Diabetes in Adults: 2020 Update - The User's Guide.
; Senior PA; Houlden RL; Kim J; Mackay D; Nagpal S; Rabi D; Sherifali D; Bajaj HS
Can J Diabetes; 2020 Oct; 44(7):592-596. PubMed ID: 32972641
[No Abstract] [Full Text] [Related]
3. Policies, Guidelines and Consensus Statements: Pharmacologic Management of Type 2 Diabetes-2015 Interim Update.
; Harper W; Clement M; Goldenberg R; Hanna A; Main A; Retnakaran R; Sherifali D; Woo V; Yale JF; Cheng AY;
Can J Diabetes; 2015 Aug; 39(4):250-2. PubMed ID: 26233723
[No Abstract] [Full Text] [Related]
4. Women with Type 2 Diabetes and Glycemic Control.
Gosse S
Medsurg Nurs; 2014; 23(5):317-20, 329. PubMed ID: 26292437
[TBL] [Abstract][Full Text] [Related]
5. Management of Daily Glycemic Fluctuations in Patients With Type 2 Diabetes.
Kushner PR
J Fam Pract; 2016 Nov; 65(11 Suppl):. PubMed ID: 28087879
[TBL] [Abstract][Full Text] [Related]
6. Improved Glycemic Control With Minimal Change in Medication Regimen Complexity in a Pharmacist-Endocrinologist Diabetes Intense Medical Management (DIMM) "Tune Up" Clinic.
Morello CM; Rotunno T; Khoan J; Hirsch JD
Ann Pharmacother; 2018 Nov; 52(11):1091-1097. PubMed ID: 29775079
[TBL] [Abstract][Full Text] [Related]
7. Effects of sitagliptin beyond glycemic control: focus on quality of life.
Sakamoto Y; Oyama J; Ikeda H; Kuroki S; Gondo S; Iwamoto T; Uchida Y; Kodama K; Hiwatashi A; Shimomura M; Taguchi I; Inoue T; Node K;
Cardiovasc Diabetol; 2013 Feb; 12():35. PubMed ID: 23432786
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular disease and glycemic control in type 2 diabetes: now that the dust is settling from large clinical trials.
Giorgino F; Leonardini A; Laviola L
Ann N Y Acad Sci; 2013 Apr; 1281(1):36-50. PubMed ID: 23387439
[TBL] [Abstract][Full Text] [Related]
9. The Influence of Proton-Pump Inhibitors on Glycemic Control: A Systematic Review of the Literature and a Meta-Analysis.
Gómez-Izquierdo JC; Yu OHY
Can J Diabetes; 2017 Aug; 41(4):351-361. PubMed ID: 28373033
[TBL] [Abstract][Full Text] [Related]
10. American Diabetes Association Standards of Medical Care in Diabetes 2017.
Marathe PH; Gao HX; Close KL
J Diabetes; 2017 Apr; 9(4):320-324. PubMed ID: 28070960
[No Abstract] [Full Text] [Related]
11. Pharmacologic Management of Type 2 Diabetes: 2016 Interim Update.
Canadian Diabetes Association Clinical Practice Guidelines Expert Committee
Can J Diabetes; 2016 Dec; 40(6):484-486. PubMed ID: 27912867
[No Abstract] [Full Text] [Related]
12. Tight glycemic control: what do we really know, and what should we expect?
Nasraway SA; Rattan R
Crit Care; 2010; 14(5):198. PubMed ID: 20875150
[TBL] [Abstract][Full Text] [Related]
13. Treatment choices for the glycaemic management of patients with type 2 diabetes and chronic kidney disease: Analysis of the SAIL patient linked dataset.
Min T; Davies GI; Rice S; Chess J; Stephens JW
Diabetes Metab Syndr; 2018; 12(2):123-127. PubMed ID: 29239764
[TBL] [Abstract][Full Text] [Related]
14. Individualizing Targets for Glycemic Control.
Burson R; Moran KJ
Home Healthc Now; 2018; 36(3):190-191. PubMed ID: 29722710
[No Abstract] [Full Text] [Related]
15. Adherence to oral diabetes medications and glycemic control during and following breast cancer treatment.
Calip GS; Hubbard RA; Stergachis A; Malone KE; Gralow JR; Boudreau DM
Pharmacoepidemiol Drug Saf; 2015 Jan; 24(1):75-85. PubMed ID: 24923811
[TBL] [Abstract][Full Text] [Related]
16. [Is there any progress in the blood glucose lowering therapy of type 2 diabetes?].
Winkler G
Orv Hetil; 2014 Aug; 155(31):1215-20. PubMed ID: 25095281
[TBL] [Abstract][Full Text] [Related]
17. Treatment of patients with type 2 diabetes with exenatide once weekly versus oral glucose-lowering medications or insulin glargine: achievement of glycemic and cardiovascular goals.
Meloni AR; DeYoung MB; Han J; Best JH; Grimm M
Cardiovasc Diabetol; 2013 Mar; 12():48. PubMed ID: 23522121
[TBL] [Abstract][Full Text] [Related]
18. Approaches to treatment 1: How is type 2 diabetes actually treated?
Bloomgarden ZT
J Diabetes; 2015 Nov; 7(6):747-8. PubMed ID: 26211568
[No Abstract] [Full Text] [Related]
19. [Antihyperglycemic treatment guidelines for diabetes mellitus type 2 (Update 2019)].
Clodi M; Abrahamian H; Brath H; Brix J; Drexel H; Fasching P; Föger B; Francesconi C; Fröhlich-Reiterer E; Harreiter J; Hofer SE; Hoppichler F; Huber J; Kaser S; Kautzky-Willer A; Lechleitner M; Ludvik B; Luger A; Mader JK; Paulweber B; Pieber T; Prager R; Rami-Merhar B; Resl M; Riedl M; Roden M; Saely CH; Schelkshorn C; Schernthaner G; Sourij H; Stechemesser L; Stingl H; Toplak H; Wascher TC; Weitgasser R; Winhofer-Stöckl Y; Zlamal-Fortunat S
Wien Klin Wochenschr; 2019 May; 131(Suppl 1):27-38. PubMed ID: 30980148
[TBL] [Abstract][Full Text] [Related]
20. Achieving glycemic goals with addition of incretin-based therapies to insulin in patients with type 2 diabetes mellitus.
Tibaldi J
Am J Med Sci; 2014 Jun; 347(6):491-501. PubMed ID: 24469234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
